Business Board nomination

Evotec Proposes Dieter Weinand as Supervisory Board Chairman

Analysis based on 10 articles · First reported Apr 07, 2026 · Last updated Apr 07, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market is likely to view Evotec's nomination of Dieter Weinand positively, as his extensive experience in the pharmaceutical industry is expected to drive commercial execution and strategic partnerships, potentially leading to increased profitability and long-term value creation for Evotec. This leadership change signals a strategic focus on strengthening Evotec's market position.

Biotechnology Pharmaceuticals

Event Summary

Evotec SE announced the proposed election of Dieter Weinand as Chairman of its Supervisory Board at the upcoming Annual General Meeting on June 11, 2026. Weinand, an industry veteran with over 30 years of experience from companies like Bayer, Pfizer, Bristol Myers Squibb, and Sanofi, is set to succeed Prof. Dr. Iris Löw-Friedrich. This nomination is part of Evotec's strategy to enhance commercial execution, foster strategic partnerships, and improve profitability. Dr. Christian Wojczewski, Evotec's CEO, emphasized Weinand's deep commercial expertise and understanding of the pharmaceutical landscape as crucial for the company's transformation. Weinand will reduce his current board commitments to fully dedicate himself to his new role at Evotec.

Key Actions

100 Evotec proposed election of new Chairman of Supervisory Board Dieter Weinand

60 Iris Löw-Friedrich concluded term as Chairwoman of Supervisory Board Evotec

40 Dieter Weinand will reduce board seats

Entities Involved

stock

Evotec

Evotec SE has proposed the election of Dieter Weinand as Chairman of its Supervisory Board, aiming to strengthen commercial execution, strategic partnerships, and long-term value creation. This move is expected to support Evotec's transformation into a more efficient and profitable company.

Importance 100 Sentiment 25

per

Dieter Weinand

Dieter Weinand has been proposed as the new Chairman of the Supervisory Board for Evotec SE. His extensive experience in the pharmaceutical industry is expected to be instrumental in enhancing Evotec's value and strengthening its collaborations.

Importance 95 Sentiment 30

per

Iris Löw-Friedrich

Prof. Dr. Iris Löw-Friedrich's term as Chairwoman of the Supervisory Board for Evotec SE will conclude, with Dieter Weinand proposed as her successor. She is recognized for her leadership and role in shaping Evotec's strategic development.

Importance 60 Sentiment 0

per

Christian Wojczewski

Dr. Christian Wojczewski, CEO of Evotec SE, expressed strong support for Dieter Weinand's nomination, highlighting his belief that Weinand will help transform Evotec into a more efficient and profitable company.

Importance 50 Sentiment 10

stock

Bayer

Dieter Weinand previously served as a member of the Board of Management of Bayer and as President, CEO, and Chairman of Bayer Pharmaceuticals AG, showcasing his extensive industry experience.

Importance 10 Sentiment 0

stock

Pfizer

Dieter Weinand has led business operations for companies including Pfizer, contributing to his over 30 years of global pharmaceutical industry leadership experience.

Importance 5 Sentiment 0

stock

Bristol Myers Squibb

Dieter Weinand's career includes leadership roles at Bristol Myers Squibb, adding to his broad experience in the pharmaceutical sector.

Importance 5 Sentiment 0

+ 3 more entities View on Dashboard

Relationships

Dieter Weinand related ↔ Evotec

Iris Löw-Friedrich related ↔ Evotec

Christian Wojczewski related ↔ Evotec

Dieter Weinand related ↔ Bayer

Dieter Weinand related ↔ Replimune Group

Dieter Weinand related ↔ Coya Therapeutics

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard